Boston Scientific will abandon its long-running program to develop Renuvia, a biodegradable plastic stent, despite promising study results as it intends to focus on treating larger and "more socially impactful problems," such as heart failure and stroke, said Dr. Ian Meredith, global chief medical officer at the company. The company, which will release Renuvia study results this fall, made the decision after Abbott Laboratories found its bioresorbable Absorb GT1 BVS demonstrated statistically significant safety issues at two years.
Boston Scientific to drop bioplastic-stent development program
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.